Use of EphB4 as a diagnostic marker and a therapeutic target for ovarian cancer

Details for Australian Patent Application No. 2008226824 (hide)

Owner VasGene Therapeutics, Inc. Board of Regents of the University of Texas System

Inventors Krasnoperov, Valery; Sood, Anil K.; Gill, Parkash

Agent Shelston IP

Pub. Number AU-A-2008226824

PCT Pub. Number WO2008/112290

Priority 60/906,764 12.03.07 US; 60/906,727 12.03.07 US

Filing date 12 March 2008

Wipo publication date 18 September 2008

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

5 November 2009 PCT application entered the National Phase

  PCT publication WO2008/112290 Priority application(s): WO2008/112290

22 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008226825-Biomass pretreatment

2008226823-Oligomer-protease inhibitor conjugates